Cytogenetic and molecular analyses are essential for the classification of childhood hematologic malignancies. Nearly all children with leukemia should have an adequate cytogenetic analysis which in 80-90% is expected to show clonal chromosomal abnormalities. Moreover, with the availability of appropriate gene probes and sophisticated molecular techniques, genetic rearrangements become detectable in the majority of leukemia patients. Genetic abnormalities often associate with particular clinical-biological characteristics of the disease. In ALL, for example, genetic alterations together with distinct immunologic and clinical features, define various subgroups. In AML, unique cytogenetic rearrangements have been identified and associated with distinct morphological subgroups. Apart from the diagnostic assessment, cytogenetic studies provide valuable prognostic information which may influence treatment choices. Molecular analysis has also become of important value in the management of children with leukemias, as it serves, for example, to identify genetic abnormalities not detected by chromosomal analysis and to monitor residual disease during treatment and follow-up. Thus, genetic analyses of leukemic cells provide information of clinical relevance as well as contributing to our understanding of leukemogenesis. Alternative classifications of acute leukemias which take into account genetic information are being proposed. The available cytogenetic and molecular data have then to be included in clinical protocols, either by selecting individualized therapies in certain leukemia subtypes or by modifiying treatment according to quantification of residual disease. We are closer to our main goal which is not only to classify 100% of childhood leukemias accurately, but to cure all of them.
Introduction
Leukemia is the most common type of childhood cancer. Acute lymphoblastic leukemia (ALL) represents approximately 80% of all pediatric leukemias, whereas acute myeloid leukemia (AML) comprises 15-20% of cases. Other types of myeloid neoplasms, such as the myelodysplastic syndromes (MDS) or chronic myeloid leukemia (CML), are seldom seen, and only a few pediatric cases of chronic lymphocytic leukemia, the most frequent leukemia in adulthood, have been described. 1 Cytogenetic analysis has become a powerful tool with which to classify acute leukemias. 2, 3 Recurrent chromosomal abnormalities present in malignant cells often correlate closely with specific clinical and biological characteristics of the disease. 2, 4 In AML, unique cytogenetic rearrangements associate with distinct morphological subgroups, such as the t (15;17) in acute promyelocytic leukemia. 1, 4, 5 In ALL, cytogenetic- 19) , have been defined. 1, 6, 7 Moreover, there are subtypes of ALL and AML that are identifiable primarily by chromosome analysis, for example ALL with the Philadelphia chromosome or AML with erythrophagocytosis and t(8;16). 3, 8 Apart from the diagnostic assessment, cytogenetic findings sometimes correlate with clinical outcome and thus, also serve as prognostic parameters which may affect the therapeutic decision. 1, 4 Several leukemia phenotype-specific chromosomal translocation or inversion breakpoints have been cloned. They were subsequently shown to interrupt oncogenes which are thought to play a causative role in leukemogenesis. 9 Chromosomal deletions, which result in the loss of the so-called tumor suppressor genes, are much less common in pediatric leukemias. 4, 10 Molecular identification of genes participating in genetic alterations has provided clinicians with breakpointspecific gene probes or sequence information to be used in new DNA or RNA diagnostic technology as a tool of critical importance in the management of children with leukemias. 11, 12 This includes identification of molecular abnormalities not detected by chromosomal analysis as well as monitoring residual disease during treatment and follow-up. 13, 14 Finally, the abnormal fusion transcripts and chimeric proteins derived from karyotypic abnormalities are also now targeted by novel therapeutic approaches. 15 Here I review the cytogenetic and molecular abnormalities associated with childhood leukemias. Firstly, a clinically useful genetic classification of childhood ALL is updated, by revisiting the classical cytogenetic abnormalities and examining in detail the newly described rearrangements of TEL-AML1, p16
INK4a /p15 INK4b , and TAL1 genes. Secondly, emphasis is given to the classification and prognostic significance of the genetic abnormalities in AML and MDS, with particular focus on those aspects which differ in children and adults. Methods and nomenclature of the molecular and cytogenetic analyses are described in Refs 12 and 16, respectively.
Incidence of karyotypic abnormalities in childhood leukemias
Currently, when the bone marrow sample is sent to the laboratory and processed properly, nearly all children with leukemia should have an adequate cytogenetic analysis, and in 80-90% of leukemias a clonal chromosomal abnormality should be identified. 2, 4, 6, [16] [17] [18] [19] [20] [21] Moreover, genetic rearrangements should be detectable in most leukemia patients with the help of fluorescence in situ hybridization (FISH) and other molecular techniques providing the availability of appropriate DNA probes. 3 Hypothetically, if all the mutations in any given leukemia are identified, we may assess the genotype and thus predict the resultant phenotype. 22 
Figure 1
Bone marrow karyotypes of metaphase cells from children with acute leukemia. G banding of the chromosomes has been performed using a trypsin-Giemsa staining technique. The abnormal chromosomes are indicated by arrows. (a) Hyperdiploidy with more than 50 chromosomes in a 4-year-old girl with acute lymphoblastic leukemia of B cell precursor CD10 + phenotype. The complete karyotype of this cell is 53,XX,+X,+6,+8,+14,+17,+18,+21. (b) The reciprocal translocation t (1;22) in an infant with acute megakaryoblastic leukemia. The complete karyotype of this cell is 45,XX,t(1;22)(p13;q13),−2.
Acute lymphoblastic leukemia
Children with ALL who according to certain biological and clinical features are included in standard-risk therapeutic subgroups presently enjoy a cure rate of more than 80%. 1, 23 For many years, cytogenetic analysis of ALL samples was largely handicapped by the poor morphology of their chromosomes. 24 Current cytogenetic techniques allow karyotypes of excellent quality, similar to those recovered from myeloid leukemia samples, to be obtained. 6, 16 Up to 90% of children with untreated ALL display karyotypic abnormalities, and complementary molecular techniques permit the detection of rearrangements in most cases. 6, 13, 16, 17 Extensive clinical studies in the 1980s revealed the independent impact of chromosomal analysis on the prognosis of such patients. 24, 25 The survival of many high-risk cytogenetic subgroups of ALL has improved remarkably with currently available therapies. [26] [27] [28] This advancement, however, does not extend to children with t(4;11) and t (9;22) , who still experience a poor survival rate. 6, 29 The FAB classification divides ALL into three subtypes designated L1, L2 and L3. The correlation between these subgroups and chromosomal abnormalities is poor, except for the L3 which associates with t(8;14 Figure 1a) . 16, 30, 31 Almost half of ALL cases with 50 or more chromosomes also display structural cytogenetic abnormalities, frequently duplications of 1q and isochromosome of 17q. 30 These patients tend to present several factors associated with favorable prognosis in ALL: age between 2 and 10 years, leukocyte count less than 10 000 × 10 6 /l, L1 morphology, and an early pre-B immunophenotype (CD10 + ). 16 Owing to the lack of recurrent translocations in the majority of these patients, no genes which specifically associate with this group have beeen cloned. As a consequence, PCR cannot be applied to monitor the disease, but interphase FISH has been useful in detecting minimal residual disease (MRD) and early relapses. 32, 33 Hyperdiploid cases are also identified by flow cytometric analysis which detects elevated blast cell DNA content, a factor associated with favorable prognosis. 34, 35 Children with ALL with Ͼ50 chromosomes experience a cure rate of more than 80% with antimetabolite chemotherapy. 1, 23, [26] [27] [28] [29] [30] [31] This favorable outcome may be explained by the high sensibility of cells to antimetabolite drugs. 36 In a review of 182 children with ALL and hyperdiploidy Ͼ50, the 5-year probability of event-free survival (EFS) for patients with 51-55 chromosomes was less than for those with 56-67 chro- mosomes (72 vs 86%). The authors explained the poorer outcome of the first subgroup by the presence of i(17q) chromosome which has been linked to worse prognosis. 30 Of these 182 cases, only three had a T cell ALL. Major cytogenetic abnormalities were seen in nine cases (four t(1;19), three t(9;22), two t(11q23)). 30 In another study involving children with ALL and hyperdiploidy, the presence of additional structural abnormalities were more frequent in the group with 47-50 chromosomes than in the group of ALL with more than 50 chromosomes. Eleven of these 86 children with 47-50 chromosomes disclosed major recurrent abnormalities (six t(1;19), three t(9;22), two t(11q23)), and T cell ALLs (seven of 86, 8%) were also more common than in the group with more than 50 chromosomes. 31 Clinically, children with 47-50 ALL had unfavorable prognostic features: older age, higher WBC and higher serum LDH. 30, 31 Survival of this subgroup was reported in previous studies as being intermediate, 16, [23] [24] [25] 28, 29 probably influenced negatively by cases with T cell phenotype or with unfavorable translocations such as t(9;22), t(4;11) or t(1;19). However, intensified therapy has improved the clinical outcome for children with ALL and 47-50 chromosomes: EFS at 4 years was 77%, similar to the subgroup with Ͼ50 chromosomes. 30, 31 Therefore, hyperdiploid ALL cases with a precursor B cell phenotype CD10
+ can be considered as a distinct clinical-biological subgroup, except for a few cases with other recurrent abnormalities or T cell phenotype, which should be excluded from this subgroup. Whether cases with 47-50 and Ͼ50 chromosomes are different types of ALL needs to be reevaluated following the exclusion of the above mentioned cases from the entire group.
ALL with hypodiploidy
Hypodiploidy (Ͻ46 chromosomes) is found in 7-8% of cases of childhood ALL, and despite lacking most ALL high-risk prognostic factors, these patients do far worse than those with hyperdiploidy. 6, 16, 24, 25, 29, 37 Rare cases of ALL with modal number of chromosomes near haploidy (Ͻ30 chromosomes)
Figure 2
FISH analysis of childhood leukemias. Examples of in situ hybridization of cosmid and YAC probes to metaphase cells of childhood leukemias with abnormalities of band 11q23. (a) Child with ALL and a t(11;19)(q23;p13.3) identified by FISH: mapping of an MLL probe (yB22B2 YAC) to the normal chromosome 11 at band 11q23 (top); the YAC is split and maps to the der(11) (bottom, left) and the der (19) have been reported; this finding is associated with a short median survival and poor prognosis, and it is therefore important to distinguish these cases from the hyperdiploid group. 6, 24, 29, 37 Early-pre-B (CD10-) ALL with rearrangement of 11q23/MLL gene Cytogenetic abnormalities of band 11q23 were identified in 53 of 669 (8%) successfully karyotyped cases of pediatric ALL. 38 The most common abnormality, t(4;11)(q21;q23), is present in 2-5% of ALLs, especially in infants less than 1 year old with hyperleukocytosis and extramedullary disease. As in other children with translocations of band 11q23 (t(11q23)), leukemic cells display L1 or L2 morphology, early pre-B immunophenotype (CD10 negative), and frequent coexpression of myeloid markers. 6, [38] [39] [40] [41] The MLL gene located in 11q23 42 is found rearranged in t(4;11) and in most of the other common and uncommon t(11q23). 43 Moreover, 70% of infants aged less than 1 year with ALL show a MLL gene rearrangement. 13, 44, 45 The AF-4 gene at 4q21 is fused to MLL in t(4;11); MLL/AF4 fusion transcripts are detectable by reverse-transcriptase PCR (RT-PCR). This technique is especially useful in tracking MRD. 46, 47 Another recurrent
Figure 3
Cytogenetic analysis of childhood leukemias with abnormalities of band 11q23. Partial karyotypes of children with t (11;19) shown in Figure 2 . The abnormal chromosomes are on the right of each pair. (a) Child with ALL and a t(11;19) (q23;p13.3): Giemsa staining (top) and quinacrine staining (bottom) of the same cell. (b) Child with AML-M5 and a t(11;19)(q23;p13.1) in two different cells studied with G-banding. Both types of t (11;19) are difficult to detect with conventional cytogenetic analysis and therefore FISH and molecular studies are of critical importance to identify these abnormalities. abnormality seen in less than 1% of pediatric ALL is t(11;19)(q23;p13.3), which fuses MLL to a gene called ENL. This translocation is difficult to detect with banding techniques, and therefore its frequency might be underestimated unless complementary FISH or molecular analysis are employed (Figures 2 and 3) . 44, 48 Survival of children with 11q23/MLL rearrangements is very short, regardless of presenting age. 13, 26, 29, 38, 39, 45, 47, 49, 50 In a series of 45 children with ALL and 11q23 karyotypic abnormalities, 22 leukemias with t(11q23) and MLL rearrangements were analyzed separately from 23 cases with deletion or inversion of 11q23, which lacked abnormality of the MLL gene. 49 The MLL gene rearrangement resulted as a powerful determinant of survival and correlated with a much inferior outcome. 38, 49, 50 Allogenic bone marrow transplantation (BMT) is the therapy of choice for ALL-MLL, as only exceptional cases can be cured with chemotherapy alone. 13, 29, 38, 39, 41, 49, 50 Pre-B ALL with t(1; 19) A t(1;19)(q23;p13) is present in 25% of children with pre-B ALL or in 5% of all pediatric ALL cases. 51, 52 The fusion transcripts of either the t(1;19), PBX-E2A, or the molecular product of its variant abnormality t(17;19)(q21;p13), HLF-E2A, are detectable by RT-PCR. 52, 53 Two distinct cytogenetic variations of the t(1;19), a reciprocal balanced t(1;19) observed in 25% of cases, and an unbalanced der(19)t(1;19) form in 75% of cases, might comprise two major clinical and biological subtypes. The first group tends to show a hyperdiploid karyotype and favorable prognosis, whereas the second group presents with pseudodiploidy and an intermediate prognosis. 54 However, the differences in outcome between the two forms seem inconsistent with the fact that the PBX-E2A fusion protein is the same in both. 52 Moreover, the poor outcome reported in early series associated with all t(1;19) as compared to other pre-B ALL 55, 56 is nowadays nullified with intensive therapy, 57 which may therefore also nullify the different outcomes of the balanced and unbalanced forms. Monitoring of MRD with RT-PCR in t(1;19) ALL has been reported to be clinically useful. 52, 58 Precursor B cell ALL with 12p abnormalities and TEL/AML1 rearrangement Karyotypic translocations or deletions of the short arm of chromosome 12 are detected in more than 10% of pediatric ALL cases. 59 However, specific recurring abnormalities such as t(6;12), t(12;18) or t(12;21) are rarely seen. 6 Using FISH, the t(12;21)(p13;q22) was identified in three of eight children with ALL without a 12p abnormality by cytogenetics. 60 Recently, a novel gene called TEL was cloned and located on 12p13 in a t(5;12) translocation. TEL gene fuses to the AML1 gene in t(12;21)(p13;q22). [61] [62] [63] The TEL-AML1 fusion product was detected in 205 of 731 (28%) children with ALL of B lineage in several series [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] (Table 2) . Therefore, the TEL-AML1 fusion gene represents one of the most common genetic lesions in ALL, identifying a subtype of B lineage without a hyperdiploid karyotype, including children aged between 1 and 10. It is remarkable that a proportion of cases co-expressed myeloid antigens. 71, 73 Prognosis for these leukemias is regarded as favorable in the majority of clinical studies. [64] [65] [66] [68] [69] [70] [71] [72] In a uniformly treated group of 170 children with ALL, outcome was superior for the 35 cases that displayed TEL rearrangement. 70 Interestingly, the TEL-AML1 fusion was found rarely in adult ALL (three of 107 cases) 74 and in infant ALL (none of 62 cases). 75 Therefore, all newly diagnosed childhood ALL should be screened for TEL rearrangements in order to identify patients suitable for less intensive or shorter therapy. The TEL/AML1 transcript was proposed as a candidate for monitoring MRD study in childhood ALL of B lineage. 71 The 12;21 translocation involving the TEL gene can be accompanied by a deletion of the other TEL gene allele, 76 suggesting that this deletion subsequent to t(12;21) provides a further proliferative advantage to the leukemic cell clone. 77 Moreover, identification of two distinct commonly deleted segments on 12p suggests that the putative loss of at least two tumor suppressor genes might participate in the pathogenesis of these leukemias. 78 Another recurring abnormality of 12p, the dic(9;12)(p12;p12), has been associated with favorable prognosis in progenitor B-ALL. 79 Philadelphia-positive ALL The t(9;22)(q34;q11), which forms the Philadelphia chromosome (Ph) and results in transcription of the BCR-ABL fusion mRNA, is seen in patients with ALL as well as in those with CML. A t(9;22) is identified in 25-30% of adult and in 3-5% of childhood cases of ALL. 1, 29, 80, 81 At the cytogenetic level, t(9;22) in ALL-Ph and CML are identical. However, the breakpoint within the BCR gene on chromosome 22 occurs in a more centromeric region in ALL-Ph than in CML cases. The BCR-ABL gene in most cases of ALL-Ph is therefore shorter, giving rise to a hybrid protein (185 kDa) smaller in size than the 210 kDa protein of CML. [82] [83] [84] In two series of adult ALL, BCR-ABL rearrangements were detected in 23-45% of patients using PCR but only in 14-22% of patients using cytogenetics. 85, 86 Clinically it is important to distinguish patients with ALL-Ph from those with CML in lymphoid blast phase, which is feasible using PCR and FISH. [87] [88] [89] Cytogenetics is also useful, as the Ph will remain during the total course of the disease in CML whereas in ALL it will disappear in complete remission. 6, 16, [90] [91] [92] Children with ALL-Ph frequently show a complete or partial deletion of chromosome 7, otherwise a rare finding in lymphoid neoplasms and CML. 93 ALL-Ph shows predominantly an early B cell phenotype CD10
+ with frequent co-expression of myeloid markers; however, pre-B and T cell phenotypes are seen in 5-10% of cases. 6, 16, 80, 81, 94, 95 Clinically, patients are generally older than 10 years, have an increased leukocyte count and frequently suffer from CNS disease. 80 However, in a recent study, no significant clinical differences were found between childhood ALL cases with and without Ph. 81 Outcome is dismal for both children and adults with ALL-Ph. In a series of 648 children with ALL, 21 (3.2%) showed BCR/ABL rearrangement which was associated with a shorter EFS. 81 The clinical impact of monitoring residual disease by quantitative PCR deserves further investigation. 96 As only few patients are cured with intensive chemotherapy, 97 allogeneic BMT is generally considered for this subgroup, 6, 24, 25, 29, 80, 81, 94, 95, 98 but autologous BMT with purging could also have potential value. 98, 99 B cell ALL (sIg + ) with t(8;14)
A karyotypic and molecular translocation t(8;14)(q24;q32), otherwise characteristic of Burkitt lymphoma, is also detected in 85-90% of B cell ALL of L3 morphology, which is con- sidered a disseminated phase of Burkitt lymphoma. [100] [101] [102] [103] [104] The t(8;14) ALL cases constitute 1-3% of all pediatric ALL, presenting in older children with abdominal tumors and CNS disease.
16,105,106 About 10-15% of cases harbor a variant of t(8;14), namely t(2;8)(p12;q24) or t(8;22)(q24;q11), all of which affect the site of the MYC proto-oncogene at band 8q24. [107] [108] [109] The MYC gene fuses with the immunoglobulin heavy chain gene (IGH) at band 14q32 in the t(8;14). In t(2;8) and t (8;22) , other immnunoglobulin genes, namely the kappa light chain (IGK) and lambda light chain (IGL) genes, are fused to the MYC gene, respectively.
11,109-111 Molecular monitoring is useful for patients suffering from the leukemic or lymphoma form of this disease. 108, 112 Survival of children with B cell ALL and t(8;14) was poor when treated as other types of ALL, but nowadays up to 80% of these patients are cured with the same short-term intensive chemotherapy protocols applied for Burkitt lymphomas, including high-dose cyclophosphamide, cytarabine, methotrexate and intrathecal chemotherapy. [113] [114] [115] [116] T cell ALL with rearrangements of TCR-␣/␤ and TCR-␥/␦ genes T cell ALL represents an heterogeneous subgroup of ALL in which a large number of distinct cytogenetic abnormalities have been identified. 6, 29, 117, 118 This disease predominantly affects boys of older age who present with hyperleukocytosis and extramedullary disease. 119, 120 Cytogenetically, clonal abnormalities are less commonly found than in B precursor ALL cases, and hyperdiploidy is rare. 30, 31, 117, 118 There is a significant overlap in the cytogenetic abnormalities identified in T cell ALL and T cell lymphoblastic lymphomas, which therefore may represent two different forms of the same disease. 118 The most common translocations, t(11;14)(p13;q11), t(10;14)(q24;q11), t(8;14)(q24;q11), t(7;11)(q35;p13) and t(7;14)(p15;q11), involve specific chromosome breakpoints known to harbour the T cell receptors genes: TCR-␣ and TCR-␦ genes within band 14q11, TCR-␥ within band 7p15, and TCR-␤ gene within band 7q35. 11, 117, [121] [122] [123] [124] These TCR genes fuse with diverse reciprocal partner genes. One example is t(1;14)(p34;q11), observed in 3% of childhood T cell ALL, where the TCR-␣/␦ genes are juxtaposed with the TAL1 gene. 125, 126 Molecular analysis has expanded the number of T cell ALL with TAL1 rearrangements to 12-26% of cases. 127 Moreover, in one series, TAL1 was expressed by the malignant cells in more than 60% of pediatric T cell ALL which either disclosed TAL1 gene rearrangements (10 of 10) or had no detectable molecular abnormalities (13 of 27). 128 Therefore, TAL1 gene is a candidate for monitoring the disease using PCR in most T cell ALL. 14, 127, 129 Similarly, HOX11 gene expression has been found in up to 33% of childhood T cell ALL, despite the rarity of detectable cytogenetic abnormalities involving 10q24. 117, 120, 130, 131 The EGIL group has proposed an immunologic classification of ALL. Here, the major subgroups of T-ALL are distinguished based on the membrane expression of TCR-␣/␤ chains (group a) and TCR-␥/␦ chains (group b). 132 While several authors agreed to separate these two clinically and phenotypically distinct T-ALL subtypes, [132] [133] [134] others remain reluctant. 135, 136 In that respect, Schott et al 137 reported a better outcome for patients with T cell ALL with TCR-␥/␦ expression. TAL1 gene rearrangements seem to be restricted to TCR-␥/␦ T cell ALL. 136, 138 The role and relationship of TAL1 and of TCR gene rearrangements in both diagnosis and monitoring of T cell ALL thus requires further investigation.
ALL with 9p abnormalities and deletion of p16
INK4a /MTS1 and p15
INK4b /MTS2 genes Cytogenetic abnormalities of the short arm of chromosome 9 (9p) are observed in 7-12% of childhood ALL cases.
139-142
They include interstitial deletions, reciprocal translocations, dicentric chromosomes and complete losses of 9p, all of them resulting in deletions of bands 9p21-22. 16 Children with ALL and 9p abnormalities tend to have leukemias with T cell phenotype, clinical lymphomatous features, and a worse prognosis than other subgrups of ALL. 140, 142 However, several authors failed to confirm these observations. 141, 143 The interferon-alpha gene cluster (IFNA) and interferon beta-1 gene (IFNB1) reside within the commonly deleted region on 9p. 144 More recently, the two cycling-dependent kinase inhibitors p16
INK4a /MTS1 and p15 INK4b /MTS2 genes were also localized within the deleted band 9p21 in several solid tumors and hematological neoplasias, particularly in ALL. [145] [146] [147] [148] These linked genes are inactivated by either homo-or hemyzygous deletions in 28-61% of childhood ALL 70, [149] [150] [151] [152] [153] [154] [155] [156] [157] (Table 3 ). In adult and pediatric ALLs of T cell lineage, p16/p15 deletions are detected more frequently (up to 80%) than in B precursor ALL. 149 153 Survival rates seem to be superior for children without p15/p16 deletions. Heyman et al 149, 150 reported that children with p15/p16 homozygous deletion did worse than those with non-deleted and hemyzygously deleted lesions grouped together. However, Rubnitz et al 70 did not confirm the superior outcome for children with ALL without homozygous p16 deletion in a uniformly treated group. In conclusion, deletion of candidate tumor-suppressor genes p16
INK4a /p15
INK4b
, the most common genetic abnormality in pediatric ALL, is detected in a hetero- Other recurrent cytogenetic abnormalities
Rare cases of ALL are characterized by specific chromosomal abnormalities, such as precursor B cell ALL with hypereosinophilia and t(5;14)(q31;q32). 6, 16, 162 This syndrome occurs in less than 1% of ALL, and involves the interleukin-3 gene (IL-3) on chromosome 5 and the IGH gene on chromosome 14. 163 Abnormalities of the long arm of chromosome 6 were identified in 11% of childhood ALL, mostly deletions from 6q15 to 6q21. 164 These ALL, however, did not display a peculiar immunophenotype, were frequently associated with other major recurrent cytogenetic abnormalities, and had a clinical outcome similar to all other ALL cases.
6,16,164

Acute myeloid leukemia
Myeloid cancers represent 15-20% of all childhood hematological neoplasias, and acute myeloid leukemia (AML) accounts for 95% of cases. 1, 165 The prognosis of AML has not improved as it has for children with ALL. Despite the fact that up to 85% of pediatric AML patients achieve remission, most of them relapse and more than 30% of childhood deaths from leukemia are the consequence of AML.
1,165-167 Allogeneic BMT is indicated in those children with an HLA-identical sibling, resulting in cure rates of 50-55%. 1, [165] [166] [167] [168] [169] [170] However, less than 40% of children treated with either autologous transplantation or intensive chemotherapy will be long-term survivors. 170, 171 These results have prompted researchers to investigate disease features with prognostic significance in an attempt prospectively to identify patients who will not respond to therapy or will relapse. 172, 173 Cytogenetic analysis reveals clonal abnormalities in 80-85% of children with AML. 18, 19, 174, 175 These studies have played an important role in refining the FAB classification of AML, either by identifying structural chromosomal abnormalities correlated with distinct FAB subtypes, or by separating similar morphological leukemia subgroups such as AML-M2 with or without t (8;21) . 3, 8, 176 The major phenotype-specific chromosomal abnormalities are detected in 50-60% of all childhood cases (Table 4) . Complementary molecular techniques identify otherwise undetected rearrangements in a few patients with apparently normal karyotypes, and therefore assign them into the well-defined morphological subgroups. 44, [177] [178] [179] However, following this scheme one-third of AML have non-specific clonal karyotypes unsuitable to categorize these leukemias. Recently, the importance of cytogenetic analysis in myeloid leukemias is emphasized by Head 177 by introducing a novel attractive revised classification of AML, which appears to be of more clinical relevance than the FAB classification.
Clinical significance of the cytogenetic stratification of childhood AML has been studied in three retrospective series. 19, 174, 175 Investigators have found different outcomes in the distinct genetic subgroups, thus suggesting that patients with poor prognosis karyotypes should be treated with more aggressive or novel therapies. 180 The role of BMT in children with favorable cytogenetic abnormalities such as inv(16), t(8;21) or t (15;17) , is still to be defined, as these patients may not require a transplant in first remission. 181 Cooperative and prospective clinical studies involving the application of modern genetic methods will be essential to subclassify all children with AML into clinical-biological entities which share similar responses to treatment. This may subsequently allow individualized therapies to be tailored and also residual leukemia to be monitored during treatment and followup. 
Numerical abnormalities
Most hyperdiploid cases of AML have only one or two extra chromosomes. 2 The more frequent gain is trisomy 8, reported in 5-10% of pediatric AMLs; trisomy 8 was found in 54 of 666 cases with adequate cytogenetic analysis included in five independent series. [18] [19] [20] 183, 184 In patients with Down syndrome and AML the incidence is higher. 185, 186 This anomaly has been described in all FAB subgroups and is not associated with any one in particular; in more than half of cases +8 is present with other recurrent abnormalities. 4 Trisomy 8 has not been found to influence leukemia prognosis except when it appears as a secondary karyotypic change in aggressive cases. 107 The extra chromosome 8, however, is useful for monitoring the disease with FISH. 187, 188 A gain of other chromosomes include: trisomy 21, which is detected in children with AML without Down syndrome, and in some cases, associates with a constitutional +21 in children with Down syndrome; 185,186,189 trisomy 22, which strongly correlates with M4Eo with inv(16); 190 and trisomy 4, a nonspecific finding in less than 1% of AML cases. 173, 191 Partial or complete loss of chromosome 7 is frequent in myeloid neoplasms. 192, 193 Leukemias with monosomy or deletion of the long arm of chromosome 7 (7q) are grouped together, as both abnormalities lead to the loss of a tumor(s) suppressor(s) gene(s) located on 7q which affect a pluripotent hematopoietic progenitor cell. [194] [195] [196] Two different regions are commonly deleted in myeloid neoplasms: 7q22 and 7q32, the latter associated with a worse prognosis. 193, 197, 198 De novo monosomy 7/del(7q) occurs in several childhood myeloid disorders, including AML and MDS. 199 In AML, −7/del(7q) is detected in about 5-7% of cases. 18, 19, 183, 184, 199, 200 In a review of 31 children and adolescents with de novo AML and −7/del(7q), the median age was 10.5 years and the sex ratio M:F was 2.2:1; leukemias were not associated with any parti-cular FAB subgroup, although −7/del(7q) was more frequent in M4 and M6, and many cases were preceded by myelodysplasia. 199 Clinical findings include bacterial infections and prolonged marrow aplasia after chemotherapy. 19, 174, 199 Uniformly, children have very low remission and survival rates. Only a few long-term survivors have been reported following allogeneic BMT, which appears to be the only curative option currently available. 19, 174, 199 Loss of a sex chromosome, X or Y, is much less common in young patients than in adults. In children, most cases are associated with a t(8;21), frequently representing secondary karyotypic events. 201 It is remarkable that monosomy 5/del(5q) is rarely observed in childhood de novo AML or MDS, while being a common finding in adults with these disorders. 1, 192 These findings are suggestive of a distinct pathogenesis of these leukemias in adults vs children.
177
Structural abnormalities: correlation with FAB subgroups t(8;21)(q22;q22) and AML-M2
The t(8;21) is the most common structural abnormality in childhood AML, almost always associated with AML-M2. 202 In seven series including 769 cases of AML, 108 children (14%) showed a t(8;21): 89 were M2 (82%), 13 were M1, and only six had other phenotypes. [18] [19] [20] 184, 200, 203, 204 These 89 cases represented 38% of all M2 cases included in these series. Cytogenetic variants of t(8;21) were detected in 1.1% of 638 cases of childhood AML in a collaborative study. 205 t(8;21) is associated with loss of the sex chromosomes in more than 60% of patients. 201, 205 This proportion is lower in childhood leukemias, ranging from 25 to 55%. Deletion of the long arm of chromosome 9 occurs non-randomly in t(8;21) AML leukemias, and was recently linked with poor outcome. 201, 206 The presence of t(8;21) and its variants identifies a subset of AML-M2 which can be distinguished morphologically from other M2 cases. [207] [208] [209] Also, a distinctive immunophenotypic pattern with expression of myeloid markers as well as CD19 and CD56, but lack of T cell antigens, has been described. 210, 211 Clinically, children are older, predominantly male, and have a high incidence of extramedullary tumor masses. 204, 209, 212, 213 They also experience high remission and survival rates, 183, 203, 204 as compared to other AML-M2 cases 184 or to all AML cases lacking t(8;21). 200, 204 However, the better clinical outcome was not confirmed to be so favorable in two series of pediatric AML 19, 174 as compared to adult AML. 173, 209, [214] [215] [216] In our experience, nine patients with t(8;21) included in a series of 115 children with AML had a poor outcome (only one was alive at 3 years from diagnosis). 19 Four had an additional del(9q) and three others initially presented with central nervous system disease; both features are associated with inferior outcomes in AML and then may contribute to the poor course of the disease. 172, 201 In a recent series encompassing 220 children with AML, 36 exhibited t(8;21) and did not do better than all the other patients. 175 It remains to be defined whether children with AML and t(8;21) should receive allogeneic BMT in first complete remission, provided a donor is available, but for now it seems a rational option. 217 At a molecular level, the t(8;21) interrupts two genes, AML1 on 21q22 and ETO on 8q22. [218] [219] [220] Molecular techniques allow for the detection of the AML-ETO fusion product in all patients with t(8;21). 220, 221 These tests have not been useful for monitoring residual disease, as AML1-ETO transcripts were also detected when examining peripheral blood of patients in long-term remission. 182, [222] [223] [224] However, two recent reports support the value of serial quantification of AML1-ETO transcripts to monitor disease progression and predict relapse in patients with AML and t(8;21). 225, 226 Acute promyelocytic leukemia (APL) AML-M3 and the t(15;17)(q22;q11.2) Childhood APL represents 3-10% of cases in several series. [18] [19] [20] 183, [227] [228] [229] [230] However, the incidence of APL in Italy, South American countries and Spain appears to be higher. [231] [232] [233] The characteristic t(15;17) is found in virtually all cases of APL, including microgranular and other variants. 5, 234, 235 Moreover, this translocation is absent in patients with any other type of leukemia or solid tumor, with the exception of CML in blasts crisis and M3 morphology. 2, 233, 234 Additional genetic alterations including trisomy 8 and, less commonly, iso(17q), are seen in up to one-third of cases and are associated with worse prognosis. 235, 236 Variant translocations are rare in APL. 237 Clinically, children with APL are predominantly of older age and female sex. They presented with low leukocyte count and frequent clotting abnormalities. 19, 174, [227] [228] [229] [230] When exposed to therapy protocols designed for AML, more than one-third of children with APL died during induction, although when in remission they had prolonged responses. 19, 174, 183, 203, 230, 231 All-trans retinoic acid (ATRA) is at present used as induction therapy along with chemotherapy, achieving complete remission in more than 80% of patients. 231, 233, [238] [239] [240] [241] [242] Post-remission chemotherapy is necessary, and long-term survival is obtained in more than 70% of children and adults. 233, [240] [241] [242] The t(15;17) fuses the RARA gene on chromosome 17 to the PML gene on chromosome 15. [243] [244] [245] [246] The chromosome 15 breakpoint falls within three different breakpoint cluster regions of the PML gene in intron 6 (bcr1, 70% of cases), intron 3 (bcr3, 20%) and exon 6 (bcr2, 10%). The chromosome 17 breakpoint occurs almost always in intron 2 within the locus that encodes for the retinoic acid receptor alpha gene (RARA). The PML/RARA fusion gene is actively transcribed as a chimeric mRNA detectable in 100% of APL cases. 247 Most variant translocations of t(15;17) usually involve the PML and RARA genes. 237 However, a subset of APLs (often with atypical morphology) exhibits variant translocations; the more significant is t(11;17), which fuses the RARA gene to a novel gene called PLZF, defining a distinctive form of leukemia which fails to respond to retinoic treatment. 248, 249 Based on the clinical response to ATRA and the insight into the molecular function of the fusion proteins, it has been sugested that disturbances of the RARA receptor gene play a major role in the pathogenesis of APL. Recently, Vyas et al 250 demonstrated the response to ATRA to be associated with maturation, subsequent loss of the mature leukemic elements, and preferential regeneration of normal hematopoietic elements in APL patients.
The detection of the PML/RARA transcripts by RT-PCR provides a rapid and extremely sensitive tool to diagnose and monitor children with APL. [251] [252] [253] Similar results have been obtained using FISH. 254 Prolonged survival is associated with the absence of the PML/RARA fusion product, and a positive RT-PCR after previous molecular remission predicts early relapse. Accurate genetic diagnosis of APL appears essential as ATRA therapy may only induce remission in leukemic cells harboring t(15;17) or variant translocations resulting in PML-RARA transcripts. 181, 238, 239, 252 Acute myelomonocytic and monocytic leukemia (AML-M4 and M5) Inversion of chromosome 16 and AMMoL-M4:
The inv(16)(p13q22), and its variant t(16;16)(p13;q22), are nonrandomly associated with acute myelomonocytic leukemia with abnormal eosinophils (AMoL-M4Eo). 255 Leukemias with inv(16) consistently display eosinophils with altered morphology and ultrastructure which allows them to be distinguished from other myelomonocytic leukemias. 207, 255 The frequency of inv(16) in children with AML ranges from 6 to 11%, and is seen in 19-36% of all M4 cases. [18] [19] [20] The vast majority of leukemias with inv(16) are classified as M4Eo; 2, 19, 107, 255 some cases, however, have other phenotypes but many of them exhibit bone marrow eosinophilia and/or abnormal eosinophils. 18, 20, [256] [257] [258] Moreover, inv(16) AML produces a specific immunophenotype accompanied by CD2 expression. 259 Trisomy 22, otherwise a very rare finding in myeloid cancers, is non-randomly associated with inv(16). 190 As in other cytogenetic subgroups, an extra chromosome 8 is sometimes present with no specific significance. Cases with del(7q) have been also reported. 107, 255 Variant abnormalities of inv(16) are extremely rare.
Children with inv(16) are generally undistinguishable from the entire group by clinical data, 18, 174, 200 although one clinical study characterized them as being older and presenting with hyperleukocytosis. 19 Remarkably, Raimondi and Kalwinsky 174 reported a high incidence of CNS disease at diagnosis (eight of 15 children with inv(16)) and at relapse (three of eight), data shown previously in adults. 260 However, frequent CNS involvement was not confirmed in other pediatric series. 19, 184 Effective CNS prophylaxis therapy thus might be necesary in this group of patients. 174 Prognosis for adult patients with AML-M4Eo and inv(16) is better when compared to other subgroups of AML. 173, 215, 216, 261 In children, complete remission was achieved in almost all patients in four clinical trials. 19, 174, 175, 183 However, in the St Jude's series survival for the inv(16) subgroup was not superior with respect to others, probably due to the high incidence of CNS disease. 174 In our experience, children with AML and inv(16) have a better EFS when compared either to all other AML-M4 leukemia or to the remaining patients, 19 thus confirming results of the adult series. Cloning of the inv(16) breakpoints identified two genes, CBFB on 16q and MYH11 on 16p. 262, 263 The fusion product CBFB-MYH11 was detected in all but two patients in a series including 37 children and adults with inv(16). 264 The corresponding CBFB-MYH11 fusion protein was detected in 20 of 22 cases of inv(16). 265 However, chimeric mRNAs are heterogeneous because of the various breakpoints observed within the MYH11 gene.
263,266,267 Also, it is still unknown whether identification of the fusion gene product predicts relapse. 181, 182, 265 Recently, Kuss et al 268 reported that in inv(16) leukemias the multidrug resistance protein gene MRP is deleted, which may contribute to the chemosensitivity and subsequently favorable prognosis of these leukemias. CBFB-MYH11 fusion transcripts were detected in about 10% of AML-M4 cases without eosinophilic abnormalities 269 and in 6% of AML with phenotypes other than M4. 270 For that reason, the use of FISH and RT-PCR is of special value as subtle chromosome 16 abnormalities are difficult to detect with conventional cytogenetics. 270, 271 Abnormalities of band 11q23 and the MLL gene:
Reciprocal translocations involving band 11q23 affect 5-8% of children with ALL, with t(4;11) and t(11;19) predominating (see above). In children with AML, 11q23 abnormalities are found in 5 to 18% of cases. 18, 183, 184, 200, 203 In five large series involving 577 children with AML, 85 (15%) revealed cytogenetic rearrangements of band 11q23. [18] [19] [20] 184, 200 In a recent review, 17% of 220 children with AML were reported to have 11q23 abnormalities. 175 This proportion is raised to near 20% when complementary FISH and molecular analysis had been instrumental for diagnosis. 44 ,179 t(9;11), t(6;11) and t (11;19) are the most common translocations, although more than 15 other genetic alterations are known. 40, 41, 272 All of them involve the same gene, MLL, which is found rearranged in about 95% of all t(11q23) by Southern blotting (Figure 4) . 42, 43 Myeloid leukemias with t(11q23) are commonly of myelomonocytic or monoblastic lineage. 1, 4, 273 In a series of 115 children with AML, 36 showed M4 or M5 leukemias, not including nine others who had M4Eo-inv(16). Eighteen of these 36 patients had t(11q23): 14 of 20 M5 cases (70%), and four of 16 M4 cases (25%). 179 Moreover, only a few AMLs with translocations or inversions of 11q23 exhibit phenotypes other than M4-M5. 18, 20, 179 As happens in ALL, 50-70% of infants with AML have 11q23 abnormalities. 40, 41, 44, 273 In a similar retrospective study of 65 adults, 11q23/MLL rearrangement was found in 11 of 40 M4 cases (28%) and in only four of 25 M5 cases (8%). 274 Frequently, AML with t(11q23) express lymphoid antigens, and bi-phenotypic leukemias often have abnormalities of band 11q23. 136, [275] [276] [277] Taken together, these observations suggest that 11q23 rearrangements affect a pluripotential progenitor cell capable of both myeloid or lymphoid differentiation. 1, 40, 41 Moreover, t(11q23) is common in therapy-related leukemias, especially in children previously treated for ALL with agents that bind to DNAtopoisomerase II. [278] [279] [280] [281] Of 59 children with AML and t(11q23) included in three series, 28 (47%) had a t(9;11)(p22;q23). All were classified as M5a with expression of myeloid and immature monocytic markers. 18, 19, 184 These cases, however, cannot be morphologically distinguished from other M5 without t(9;11). The remaining children with other 11q23 abnormalities represent a heterogeneous population with different translocations such as t(6;11), t(11;19), t(10;11) and t(11;17). 4, [18] [19] [20] 184 Children with t(9;11) are clinically indistinguishable from other patients with M5 leukemias lacking t(11q23). In contrast, children with other translocations of 11q23 display aggressive features such as hyperleukocytosis, CNS disease, organomegaly and skin involvement. 19, 174 Myeloid leukemias with t(11q23) have a poor outcome in most adult series, 173, 215, 216, 282 although this prognostic significance may be absent in elderly patients. 274 In two retrospective series of AML, survival for children with t(9;11) was superior when compared to patients with other t(11q23), who all had a dismal outcome. 19, 174, 179 These surprising results were confirmed by Leblanc et al, 175 reporting a better outcome in 16 children with t(9;11) than in 21 cases with other t(11q23) abnormalities (Table 5 ). Why patients with t(9;11) do better than those with other t(11q23), all of which involve the MLL gene, is unknown. It may be explained in part by: (1) the impact of the other partner gene in the translocation; 40, 41 (2) the good response of M5-t(9;11) leukemias to VP-16; 4, 283 and (3) the lower incidence of hyperleukocytosis, skin and CNS involvement in the t(9;11) group. 19, 174 These findings should translate into therapeutic strategies tailored for these two subgroups of childhood AML. The favorable prognostic significance of t(9;11) has yet to be confirmed in adults, where t(9;11) is less common.
The combination of cytogenetic, FISH, and molecular analysis provides a highly sensitive strategy for the detection of 11q23/MLL gene rearrangements in childhood leukemias, which is essential as the MLL status is such a powerful prognostic determinant (Figures 2 and 3) . 40, 44, 179, 284, 285 Despite the heterogeneity of genes located on partner chromosomes fused to MLL, Southern blotting and RT-PCR are capable of detecting 100 and 90% of these MLL rearrangements, respectively. Screening for multiple translocations in a single PCR reaction will be of clinical importance once available. 12, 40, 41, 43, 46, 286 t(8;16)(p11;p13) and AML M4-M5: t(8;16) is non-randomly associated with AML-M4 and M5 with erythrophagocytosis. [287] [288] [289] [290] Its incidence is very low (0.33-2.2% of all AML cases). 289, 291 A few cases with similar clinical-biological features display variants of t(8;16), which always involve the 8p11 breakpoint. 291 Fourteen patients aged less than 20 years with leukemia and t(8;16) have been reported. 18, 19, [287] [288] [289] [290] [291] [292] [293] [294] [295] [296] They can be separated into two subgroups according to age at diagnosis: infants (eight cases, including four congenital Table 5 Clinical response of children with acute myeloid leukemia according to cytogenetic subgroup leukemias), and older children (five older than 13 years, and one aged 8 years). Ten cases were classified as M5 and four as M4, and erythrophagocytosis was demonstrated in 10 of 13 cases with available data. Clinically, hepatosplenomegaly and lymphadenopathy were present in most of the cases (seven of 10), and skin involvement was also frequent (four of 10). CNS disease was not reported. As in adult cases, survival was poor with only four children surviving more than 6 months. 19, [287] [288] [289] [290] [291] [292] [293] [294] [295] [296] Recently, Borrow et al 297 cloned the t(8;16) breakpoint. It involves a gene for acetyltransferase at 8p11 (MOZ) fused to a gene for a CREB binding protein CBP at 16p13. With the availability of sequencing data, molecular recognition and monitoring of these leukemias is possible. t(6;9)(p23;q34):
The translocation t(6;9) was first described to be associated with AML by Rowley et al 298 in 1976 . Less than 60 cases have been reported to date, representing 0.5-4% of all AMLs.
299, 300 Patients are younger than in other types of leukemia (median age, 28 years). They have AML-M2 or M4, often associated with bone marrow basophilia and preceding MDS.
299 Only 20 reported cases were aged less than 20 years, most of them young adults. 19, 20, [300] [301] [302] [303] [304] [305] [306] [307] [308] Ten had M4, eight M2, one M1 leukemia and one MDS. A preceding MDS was described in all eight cases with available information, and bone marrow basophilia in only three of 17 patients. Prognosis is uniformly poor, but it seems slightly better in young adults. 300 Molecular analysis of t(6;9) has shown that the breakpoint in 9q34 is different than the one identified in the typical t(9;22). 309 The two genes involved in the t(6;9), DEK on 6p23 and CAN on 9q34, fuse in a chimeric DEK-CAN mRNA which is useful for diagnosis and monitoring of the disease. 300, 310, 311 Erythroleukemia or AML-M6 This form of leukemia represents only 1-2% of all childhood AML cases. 167, 312 In a series by Malkin et al 312 including 10 cases and reviewing 14 more, children had a median age of 4.7 years, male predominance, frequent Down syndrome, and a poor response to chemotherapy with frequent relapses. Cytogenetically, two major subgroups of AML-M6 can be dis-tinguished: (1) patients with complex karyotypes, generally with abnormalities of chromosomes 5 and 7 (complete losses, deletions or balanced translocations), who share biological and clinical features with therapy-related AML, including a poor prognosis; and (2) patients with simple or not detectable cytogenetic abnormalities, who commonly have a de novo AML-M6 picture with more favorable prognosis. 313, 314 Of the 42 children and adolescents with AML-M6 and cytogenetic analysis previously reported, 19, 20, 200, 204, 312, [314] [315] [316] [317] [318] [319] [320] [321] [322] [323] [324] [325] 12 had a normal karyotype at diagnosis (29%). This percentage is higher compared with nine of 78 cases (12%) included in three major adult series. 313, 314, 319 Moreover, complex karyotypes were reported in 33% of children vs 80% of adult cases. The most common karyotypic change was monosomy 7/del(7q) (nine of 42 cases), but in contrast to adult AML-M6, it was present as a single cytogenetic abnormality in most patients. Other findings included trisomies of chromosomes 8 and 21 (six cases each), whereas deletion of 5q, common in adults, was absent. Five of 42 childhood cases had Down syndrome. Therefore, most children with AML-M6 can be ascribed cytogenetically to the group characterized by single abnormalities, frequently −7/del(7q) or normal karyotypes, and a somewhat better prognosis.
Acute megakaryoblastic leukemia or AML-M7 AML-M7 comprises 3-5% of all childhood AML and about 20% of infant leukemias. 1, 165, 326 Detection of platelet peroxidase (PPO) activity by electron microscopy and recognition of platelet glycoprotein antigens has facilitated the diagnosis of AML-M7, resulting in an increase in its reported frequency. [326] [327] [328] [329] Children with AML-M7 can be classified according to the cytogenetic analysis into four different subgroups. 330 
AML-M7 and Down syndrome (DS):
DS is associated with a 20-fold increased risk of developing leukemia during childhood, both ALL and AML. 185, 331 Unique features of AML in DS patients are: a 500-fold higher incidence of AML-M7; a frequent presentation with myelodysplasia or transient leukemia; and frequent dyserythropoiesis in bone marrow with coexpression of T cell antigen CD7 on blast cells. 331, 332 Forty children with DS have been identified among 633 patients in the cooperative BFM studies for AML. 332 Advances in diagnostic methods permitted the classification of almost all myeloid leukemias in DS as AML-M7. 185, 186, [331] [332] [333] On the other hand, half of children with M7 leukemias have DS. 185, 326, 330 Although no specific hallmarks were identified, cytogenetic analysis had shown absence of t(1;22), frequent trisomy 8, and less commonly, trisomies 1 and 21. 185, 186, 326, 328, [330] [331] [332] [333] [334] The presence of an extra copy of chromosome 21 in transient megakaryoblastic leukemia seen in infants with DS, which in a quarter of cases will finally develop AML-M7, is likely to be involved in the pathogenesis of transient leukemia. 164, 166, 331 Children with AML and DS have a markedly superior outcome compared to those without DS, especially with regimens containing high-dose cytarabine. 166, 332, [335] [336] [337] AML-M7 and acquired trisomy 21: In a review, acquired trisomy 21 was found in eight of 68 children suffering from AML-M7 without DS. 330 Trisomy 21 was also found in four patients with t (1;22) , and in six children with DS, representing an overall frequency of 24% of all childhood AML-M7 cases. 330 There are no data available regarding the prognostic influence of acquired +21 in AML. t(1;22)(p13;q13) and AML-M7:
The 1;22 translocation has been described exclusively in very young children with AML-M7, representing approximately one-third of childhood AML-M7 (Figure 1b) . [338] [339] [340] [341] [342] [343] [344] [345] Common features present in 24 patients reported to date 19, [338] [339] [340] [341] [342] [343] [344] are median age of 6 months, absence of Down syndrome, transient leukemia or myelodysplasia and massive organomegaly. Several cases were misdiagnosed as solid tumors prior to cytogenetic analysis. 19, 344 A hyperdiploid karyotype was seen in 25% of cases with t (1;22) . 345 Prognosis appears to be very poor, 345 although several patients were long-term survivors following autologous BMT. 19, 339, 340, 344 Cloning of genes involved in t(1;22) is important and might help to identify more patients with this abnormality.
AML-M7 with abnormalities of bands 3q21 and 3q27, and monosomy 7/del 7q:
These karyotypic changes are relatively common in adult AML-M7, but only a few cases have been described in children, most of them young adolescents. 330 As in older patients, most children with 3q21-3q26 abnormalities suffered from myeloid malignancy, predominantly AML-M7 with trilineage myelodysplasia, and experienced poor prognosis.
346-349
The myelodysplastic syndromes (MDS) MDS are very rare in children, representing 3% or less of all hematopoietic malignancies. [350] [351] [352] [353] [354] More than 80% of childhood MDS belong, according to the FAB criteria, in the more advanced stages, namely refractory anemia (RA) with excess of blasts (RAEB), RA with excess of blasts in transformation (RAEB-t), and chronic myelomonocytic leukemia (CMML), whereas RA and RA with ringed sideroblasts (RARS) are much less common than in adults. [350] [351] [352] [353] [354] [355] [356] [357] [358] [359] [360] [361] [362] Predisposing conditions for childhood MDS include constitutional chromosomal disorders (Down syndrome), neurofibromatosis, Schwachman syndrome, Kostmann's neutropenia and Fanconi's anemia. 350, 351, 358 Familial occurrence of MDS, mostly associated with monosomy 7, has been reported, and clinicians should always consider the possibility that a child who presents with MDS or AML and monosomy 7 may have a familial disorder. 195, 196 Cytogenetic analyses are essential for the evaluation of a child with proven or suspected MDS. 351 Recently, Chan et al 362 have emphasized the value of chromosome studies to differentiate childhood MDS from AML with low blast count, the latter having a better response to therapy. In three reviews including 137 children with MDS, 88 (64%) had an abnormal karyotype at diagnosis, 20 ,350,358 a higher incidence than in adult MDS. 359, 360 Monosomy 7/del(7q) was the most frequent abnormality, found in 45% of abnormal cases. More significant is that abnormalities of chromosome 7 are not part of the complex karyotypes commonly seen in adults, but are found as single chromosomal changes. 192, 199 In a recent review from the EWOG-MDS of 110 children with myeloid disorders and monosomy 7/del(7q), 79 had MDS and 32 had AML. 363 Monosomy 7 predominated in MDS cases, mainly as a single abnormality, whereas del(7q) was more frequent in AML. In our experience, 12 cases of childhood MDS were seen at La Fé Children's Hospital in Valencia, Spain between 1982 and 1992; five had a normal karyotype, including one with a constitutional t (13;14) , four displayed monosomy 7, one of them included a complex karyotype, one disclosed a del(5q) with other anomalies, and two showed other abnormalities (JM-C, unpublished). Other cytogenetic abnormalities observed in MDS include trisomies of chromosomes 8, 9 and 19, del(12p), del(17p), and much less frequently than in adults, deletion of 5q. 192, 350, 351, 358 The monosomy 7 syndrome (M7S), a form of MDS with bone marrow dysplasia, bacterial infection and skin rash, affects almost exclusive young children. [364] [365] [366] The juvenile chronic myelomonocytic leukemia (JCML) is diagnosed in children with a marrow picture resembling adult CMML, increased fetal hemoglobin level and lack of t(9;22)/BCR-ABL rearrangement. 199, 358 M7S and JCML share many clinical and epidemiological features, and there is controversy about whether they represent distinct disorders. 199, 350, 351, 358, 366 For example, in a review of 46 children with JCML, 11 (24%) showed monosomy 7 in the bone marrow. 199 According to an excellent review by Luna-Fineman et al, 199 M7S is one of the entities associated with chromosome 7 loss whereas JCML is a myeloproliferative disorder associated with monosomy 7 in 6-24% of cases. In contrast, other authors do not delineate M7S as an independent entity as such cases either fall into JCML or can be otherwise classified according to the FAB criteria. 351, 354, 355 Rapid transformation into AML despite therapy is a general rule for all preleukemic states with monosomy 7, and survival is very short. 20, 351, 358 However, Passmore et al 358 reported a much better significant survival for 10 patients with M7S when compared to JCML cases in which all except one of 19 died.
In a review of 58 children with MDS which were treated with intensive chemotherapy, 52% achieved complete remission and only 17% remained free of disease. 367 Therefore, allogeneic BMT is considered as a potential curative option with survival rates of 50-60%. 367 Moreover, BMT is generally indicated in most cases with abnormalities of chromosome 7. 1, 199 In the EWOG-MDS childhood series, four factors were found to be significantly associated with better outcome: patients with RA vs other subgroups of MDS and AML, complete vs partial monosomy 7, monosomy 7 alone vs monosomy 7 plus additional abnormalities, and allogeneic BMT vs other therapies. 363 In conclusion, partial or total loss of chromosome 7 is observed in a heterogeneous group of pediatric myeloid disorders including AML and MDS, which should be separated from other types of MDS such as JCML. Allogeneic BMT is the optimal treatment in most cases. The only exceptions from the imperative use of BMT might be infants aged less than 6-12 months with M7S, who may enjoy prolonged responses to chemotherapy. 199, 351, 358, 363 Therapy-related AML and MDS Therapy-related MDS and AML (t-MDS/AML) in children are extremely rare, affecting less than 1% of childhood cancers overall. They occur after a latent period of a few years to as long as 10 years following treatment for other cancers, and are strongly associated in more than 90% of cases with acquired chromosomal abnormalities. 279, 281, 368 The karyotypes of 50 patients aged less than 20 years with t-MDS/AML have been reported. [278] [279] [280] Of the 50, 17 had abnormalities of chromosomes 5 or 7 (34%), most of whom had been previously treated with alkylating agents. These secondary leukemias present with features of trilineage myelodysplasia which often evolve to AML. Twenty cases disclosed 11q23 abnormalities (40%), and virtually all were exposed previously to epipodophyllotoxins and/or anthracyclines as part of treatment for ALL or solid tumors. No signs of marrow dysplasia were observed in them. Prognosis for these two subgroups of secondary myeloid disorders is very poor despite all the available therapeutic options. [278] [279] [280] [281] 368 
